Equities

Nanjing Vazyme Biotech Co Ltd

688105:SHH

Nanjing Vazyme Biotech Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)18.24
  • Today's Change0.47 / 2.64%
  • Shares traded876.48k
  • 1 Year change-34.32%
  • Beta--
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments3,4813,2643,454
Total Receivables, Net366855334
Total Inventory346364242
Prepaid expenses378221
Other current assets, total0.010.01--
Total current assets4,2304,5654,051
Property, plant & equipment, net836785343
Goodwill, net130130--
Intangibles, net1015017
Long term investments472218
Note receivable - long term----0.22
Other long term assets14678.32
Total assets5,7466,0054,607
LIABILITIES
Accounts payable147293119
Accrued expenses116272106
Notes payable/short-term debt1,1322980
Current portion long-term debt/capital leases465831
Other current liabilities, total78233132
Total current liabilities1,5201,154387
Total long term debt10712860
Total debt1,28548491
Deferred income tax1.51110.87
Minority interest(0.11)3.200
Other liabilities, total8910032
Total liabilities1,7171,396480
SHAREHOLDERS EQUITY
Common stock400400400
Additional paid-in capital2,4422,4292,422
Retained earnings (accumulated deficit)1,2091,7801,305
Treasury stock - common(20)----
Unrealized gain (loss)------
Other equity, total(1.72)----
Total equity4,0294,6094,127
Total liabilities & shareholders' equity5,7466,0054,607
Total common shares outstanding399400400
Treasury shares - common primary issue0.6200
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.